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ABSTRACT
Metastatic bone and soft tissue sarcomas often relapse after chemotherapy (CHT) and molecular targeted
therapy (mTT), maintaining a severe prognosis. A subset of sarcoma cancer stem cells (sCSC) is hypothesized to
resist conventional drugs and sustain disease relapses. We investigated the immunotherapy activity of cytokine
induced killer cells (CIK) against autologous sCSC that survived CHT and mTT. The experimental platform
included two aggressive bone and soft tissue sarcoma models: osteosarcoma (OS) and undifferentiated-
pleomorphic sarcoma (UPS).
To visualize putative sCSC we engineered patient-derived sarcoma cultures (2 OS and 3 UPS) with a
lentiviral sCSC-detector wherein the promoter of stem-gene Oct4 controls the expression of eGFP.
We visualized a fraction of sCSC (mean 24.2 ± 5.2%) and confirmed their tumorigenicity in vivo. sCSC
resulted relatively resistant to both CHT and mTT in vitro. Therapeutic doses of doxorubicin significantly
enriched viable eGFP+sCSC in both OS (2.6 fold, n = 16) and UPS (2.3 fold, n = 29) compared to
untreated controls. Treatment with sorafenib (for OS) and pazopanib (for UPS) also determined enrich-
ment (1.3 fold) of viable eGFP+sCSC, even if less intense than what observed after CHT.
Sarcoma cells surviving CHT and mTT were efficiently killed in vitro by autologous CIK even at
minimal effector/target ratios (40:1 = 82%, 1:4 = 29%, n = 13). CIK immunotherapy did not spare sCSC
that were killed as efficiently as whole sarcoma cell population. The relative chemo-resistance of sCSC
and sensitivity to CIK immunotherapy was confirmed in vivo. Our findings support CIK as an innovative,
clinically explorable, approach to eradicate chemo-resistant sCSC implicated in tumor relapse.
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Introduction
Bone and soft tissue sarcomas (STS) are an heterogeneous group
of solid tumors of mesenchymal origin. Undifferentiated pleo-
morphic sarcoma (UPS) is among themost frequent STS in adults
(10-20%),1,2 osteosarcoma (OS) is the most common primary
bone tumor occurring predominantly in adolescents and young
adults.3
Multidisciplinary treatment significantly improved the
outcome of patients with early stage UPS and OS.4-7
Nonetheless, the prognosis of patients with relapsing and
metastatic disease still remains poor, with 5-year overall
survival approximately ranging between 10 and 30%
regardless the use surgery, chemotherapy, molecular tar-
geted therapy and radiotherapy.8-14 This clinical scenario
is in high need of research efforts for new therapeutic
strategies, including the exploration of immunotherapy
that has significantly improved the prognosis of patients
with melanoma and is currently being explored in other
solid tumors. The clinical successes recently observed with
checkpoint inhibitors, however have not been replicated in
the initial sarcoma trials. This is likely due to their rela-
tively minor neo-antigen load and the presence of impor-
tant immunosuppressive elements in the tumor
microenvironment.15,16 In this field, a promising immu-
notherapy approach is based on the adoptive infusion of
antitumor immune-effectors, with important results
recently reported against selected cases of synovial sar-
coma treated with anti-NY-ESO1 engineered T
lymphocytes.17-21
Whatever may be the new strategy explored, a crucial
emerging and still unsolved issue is the ability to target
cancer stem cells (CSC). CSC represent a sub-type of
tumor cells involved in tumor propagation, therapy resis-
tance, recurrence and metastatisation.22-29
We recently reported that putative sarcoma CSC
(sCSC), in patient-derived STS and OS cultures, could be
visualized by their selective activation of the stemness
gene promoter OCT4.30 We also provided proof of con-
cept that sCSC could be killed in vitro by a MHC-inde-
pendent immunotherapy approach based on Cytokine-
Induced Killer cells (CIK).30,31 We now asked whether
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sCSC were resistant to chemo and targeted therapies cur-
rently used in clinical practice, exploring if a sequential
immunotherapy with CIK might be effective against
chemo- and target- therapy resistant sCSC.
CIK are ex vivo expanded T lymphocytes, endowed with T-NK
phenotype and intense MHC-independent antitumor ability32-36
mainly mediated by the NKG2D receptor that binds stress indu-
cible ligands (MIC A/B; ULBPs) selectively expressed on various
tumor histotypes including sarcomas.35-37
CIK may be an intriguing therapeutic option as they would
be applicable to all patients,38-40 regardless their HLA haplo-
type, and would not be affected by HLA-downregulation, a
common tumor immune-escape mechanism41-43 recently
associated also with CSC.44,45
We set an autologous experimental platform with UPS
and OS patient-derived cultures. We assessed their sCSC
relative resistance to both chemotherapy (doxorubicin)
and molecular targeted drugs (sorafenib or pazopanib)
along with the sequential activity of autologous CIK cells
against the resistant sCSC.
Results
Putative sCSC survive chemotherapy and molecular
targeted therapy
Visualization of putative sCSC
We successfully detected putative sCSC in 5 patient-derived sar-
coma cell cultures (OS, n = 2; UPS, n = 3) generated from biopsies
of advanced sarcomas.
Visualization of putative sCSC was performed by a gene trans-
fer strategy, previously validated in our lab, based on stable
transduction of sarcoma cells with a lentiviral vector encoding
eGFP under control of the promoter regulatory element of the
stemness gene Oct4 (LV-Oct4.eGFP). With this approach the
average rate of eGFP+sCSC within the 5 sarcoma cultures was
24.2 ± 5.2% (mean ± SEM).
Oct4, Sox2 andAldehydeDehydrogenase (ALDH), reported in
literature as molecules associated with CSC phenotype, were
assessed in all sarcoma samples with average expression of 18 ±
3.5%, 28 ± 6.8%, and 3.5 ± 1.3% (mean ± SEM), respectively. A
complete phenotype description of sarcoma cultures, including
the main ligands recognized by CIK cells is summarized in
Table 1.
All sarcoma cultures were confirmed to retain membrane
expression of HLA class-I molecules (> 99% HLA-ABC+).
The expression of NKG2D ligands MICA/B, ULBP 2-5-6
and ULBP3 was comparable in both eGFP+sCSC and eGFP–
sarcoma cells (Fig. 1).
In vivo tumorigenicity of putative sCSC
To assess the tumorigenic potential of putative eGFP+sCSC,
we subcutaneously transplanted NOD/SCID mice (n = 4) with
eGFP+ sorted sCSC from 2 different UPS (S1 and S3). In both
cases tumors grew in all mice starting 4 weeks after transplant.
We confirmed the persistence of eGFP+sCSC in tumors
explanted (8 – 13 weeks after tumor growth) at the end of
the experiment (Fig. 2).
In a selected experiment we performed a limiting dilution
assay to explore the different tumorigenic potential of eGFP+
and eGFP– sarcoma cells. We assessed the rate of S3 primary
culture (UPS) growth in NOD/SCID mice, subcutaneously
implanted with progressively scalar doses (from 7 × 104 to
0.7) of both eGFP+ and eGFP– sorted tumor cells. At the dose
of 7 × 103 tumor cells 67% (n = 4/6) of tumors grew from
eGFP+ sarcoma cells, while no tumor growth was observed (n
= 0/6) from the eGFP– group (p = 0.03).
Sensitivity of putative sCSC to chemotherapy and
molecular targeted therapy in vitro
We explored the sensitivity of putative sCSC to conven-
tional chemotherapy and molecular targeted therapy. We
used doxorubicin as chemotherapy for all 5 sarcomas,
while we used pazopanib and sorafenib as targeted therapy
for UPS and OS, respectively. We evaluated the percentage
of tumor lysis and the rate of residual sCSC after each
treatment. Putative sCSC displayed a relative resistance to
both chemotherapy and molecular targeted therapy.
Doxorubicin used at therapeutic doses (range IC50 –
IC75) determined a significant enrichment of viable
eGFP+sCSC (UPS: mean 2.3 ± 0.2 fold, n = 29; OS:
mean 2.6 ± 0.3 fold, n = 16; p < 0.0001, Fig. 3 and
Table 2) compared to untreated controls. Similarly, treat-
ment with sorafenib and pazopanib also determined an
enrichment of viable eGFP+sCSC even if it was less
intense than what observed after chemotherapy (UPS:
mean 1.3 ± 0.03 fold, n = 24 p < 0.0001; OS: mean 1.3
± 0.1 fold, n = 15, p = 0.009; Fig. 3 and Table 2).
CIK are effective against sCSC that survive
chemotherapy or molecular targeted therapy
Generation of CIK from patients
We explored the activity of CIK against sCSC that survived
chemotherapy (doxorubicin) or molecular targeted therapy
(pazopanib and sorafenib, for UPS and OS, respectively).
Table 1. Patients’ characteristics and corresponding sarcoma cell cultures.
Pts. Diagnosis Age MICA/B (%) ULBP1 (%) ULBP2-5-6 (%) ULBP3 (%) CD155 (%) CD112 (%) OCT4 (%) Sox-2 (%) ALDH high (%)
S1 UPS 67 17 1 99 19 2 1 24 14 3
S3 UPS 86 61 1 100 64 72 3 29 35 4
S5 UPS 72 1 2 97 50 7 2 15 20 8
S16 OS 58 85 7 100 75 20 14 7 44 3
S22 OS 18 49 1 99 60 8 6 10 10 1
Main ligands recognized by CIK (MICA/B, ULBP 1, 3, 2-5-6, CD112 and CD155) were expressed at variable levels by all sarcomas. Average expression of CSC markers
Oct4, Sox2 and Aldehyde Dehydrogenase (ALDH) are also reported in the table.
Abbreviations: UPS, Undifferentiated Pleomorphic Sarcoma; OS, Osteosarcoma
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CIK were generated from patients with UPS (n = 3) and
OS (n = 2). In 4 out of 5 cases we could reproduce an
autologous setting as CIK were expanded from the same
patients from whom we had generated the sarcoma cell cul-
tures described above. In 1 case (patient S22) PBMC were not
available and CIK were obtained from a third party (allo-
geneic) metastatic OS patient.
CIK were successfully ex vivo expanded within 3 – 4 weeks
of cultures from fresh or cryopreserved PBMC according to
the standard protocol that includes timed addition of IFN-Ɣ,
Ab anti-CD3, and IL2.30,31
The median expansion of bulk CIK, calculated on the total
CD3+ fraction, was 40 fold (range, 24 – 90). The subset of mature
CIK co-expressing CD3 and CD56 molecules (CD3+CD56+) was
present with a median of 35% (range 28 – 60%), while 85% (range
58 – 95%) of CD3+ cells were also CD8+ (Fig. 4). The median
membrane expression of the NKG2D receptor, main responsible
for tumor recognition, was always > 80% (Fig. 4).
The presence of pure NK (CD3–CD56+) cells within
mature CIK was negligible, median 0.5% (range 0.2 – 1.2%).
The main characteristics of patients and relative CIK
expansion data are reported in Table 3.
Figure 2. In vivo persistence of tumorigenic sCSC. Subcutaneous implantation of eGFP+sCSC (S3) generated tumors in NOD/SCID mice (n = 4). eGFP+sCSC persisted in
vivo and were recovered in explanted tumors at the end of the experiment.
Figure 1. Expression of NKG2D ligands in putative sCSC. Representative flow-cytometry dot plots reporting the comparable membrane expression of NKG2D ligands
in eGFP+sCSC and the eGFP– counterpart (S16). Quadrants were set based on negative controls, separately assessed for eGFP+ and eGFP– fraction.
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CIK kill sCSC surviving chemotherapy and molecular
targeted therapy
Patient-derived CIK efficiently killed in vitro sarcomas enriched in
putative sCSC after treatment with IC50 doses of chemotherapy
(doxorubicin 0.1 µM) and molecular targeted therapy (pazopanib
30 µM for UPS; sorafenib 5 µM for OS). We could reproduce the
autologousCIK/sarcoma targetmatching in 4/5 cases. In the single
case (S22) where autologous PBMC were not available, allogeneic
CIK from a patient with OS were used.
Mean values of tumor specific killing against chemo-sur-
viving sarcomas at progressively decreasing effector/target
(E/T) ratios were 87 ± 2% (40:1), 80 ± 4% (20:1), 70 ± 3%
(10:1), 68 ± 3% (5:1), 59 ± 5% (2.5:1), 49 ± 3% (1:1), 45 ±
3% (1:2) and 35 ± 4% (1:4) (n = 7, Fig. 5A). The observed
killing activity was comparable with that obtained against
untreated controls (n = 9, p = 0.89) (Fig. 5A).
CIK were equally effective against sarcomas that survived
treatment with molecular targeted therapy. Mean values of
tumor specific killing at progressively decreasing effector/tar-
get (E/T) ratios were 83 ± 3% (40:1), 77 ± 5% (20:1), 72 ± 7%
(10:1), 66 ± 9% (5:1), 59 ± 9% (2.5:1), 48 ± 10% (1:1), 48 ±
15% (1:2) and 40 ± 12% (1:4) (n = 6, Fig. 5B). The observed
killing activity was comparable with that obtained against
untreated controls (n = 8, p = 0.99) (Fig. 5B).
We confirmed by flow cytometry that the antitumor activ-
ity of CIK involved sCSC. We did not observe enrichment of
eGFP+sCSC in any point of the immunotherapy CIK killing
curve, against targets recovered after either chemotherapy or
molecular targeted therapy, compared to controls (Fig. 5). The
absence of relative increase of eGFP+sCSC indirectly confirms
their susceptibility to immunotherapy with CIK.
In a selected in vivo experiment (S1 UPS) we confirmed
that sCSC are relatively chemo-resistant while sensitive to
autologous CIK immunotherapy.
Both doxorubicin (5mg/Kg, day 1, n = 5) and CIK immu-
notherapy (days 1, 3 and 5, n = 4) delayed tumor growth (mean
volume fold increase 1.4 ± 0.2 and 2.7 ± 0.4 respectively) com-
pared to untreated controls (mean volume fold increase 4.9 ± 1.4,
n = 3) but, while a relative enhancement of residual sCSC (mean
62 ± 6.8% vs 29 ± 0.3%, Fig. 6) was observed in tumors explanted
following chemotherapy, the rate of sCSC after CIK immunother-
apy remained comparable with untreated controls (mean 30 ±
1.7% vs 29 ± 0.3%, Fig. 6).
A sequential chemo-immunotherapy treatment with
Doxorubicin (5mg/Kg, day 1) and CIK (day 5) reestablished
the rates of eGFP+sCSC back to levels comparable with
untreated controls (mean 37 ± 4.7% vs 29 ± 0.3%, Fig. 6),
while maintaining the delay of tumor growth (mean volume
fold increase 2.5 ± 0.4, n = 6).
Discussion
In this work we reported the preclinical activity of immunother-
apy with CIK against sCSC that survived treatment with che-
motherapy and molecular targeted therapies, commonly used in
the clinical practice. Results are generated in an autologous-
matched patient-derived preclinical setting, in the effort to
enhance data reliability in clinical perspective.
We previously provided preclinical proof of concept that
CIK were active against OS and STS, including a subset of
cells with stemness features.30 Here, we advanced to the next
experimental level, closer to a pragmatic clinical scenario. We
demonstrated that sCSC are relatively resistant to chemother-
apy and target therapies but susceptible to MHC-independent
immunotherapy with autologous CIK cells.
The approach for visualization of CSC is based on the
selective ability of putative sCSC to activate the promoter of
stemness gene Oct4. This was previously described and vali-
dated by our group.30,31,46 We provide a new functional angle
of analysis, exploring the sensitivity of putative sCSC to con-
ventional chemotherapy. We acknowledge that the proposed
methodology to visualize sCSC has objective limitations and
cannot guarantee to capture all the “true” sCSC. This would
be however beyond the scope of our research work. What this
system allows to highlight is that tumor cells with stemness
features, like the ability to activate Oct4 and enhanced
Figure 3. Sarcoma CSC are relatively resistant to chemotherapy and mole-
cular targeted drugs. Therapeutic doses of doxorubicin significantly enhanced
the residual rates of sCSC (visualized as eGFP+) in both UPS (n = 29) and OS (n =
16), supporting the hypothesis of their relative chemo-resistance. Similar result,
but less intense were observed following treatment with targeted drugs pazo-
panib (UPS, n = 24) and sorafenib (OS, n = 15). Cumulative data (mean fold ±
SEM) of eGFP+sCSC enrichment in UPS and OS following treatments are reported
in the figure.
Table 2. Dose dependence of sCSC enrichment by chemo and target therapy.
eGFP+CSC Increase (fold)
Chemotherapy Targeted therapy
Pts. IC50 IC75 IC50 IC75
S1 (UPS) 2,5 3,3 1,3 1,3
S3 (UPS) 1,5 2,2 1,3 N/A*
S5 (UPS) 1,9 4 1,3 1,1
S16 (OS) 2,1 4,3 1,1 2,1
S22 (OS) 2,1 3,5 1,2 1,4
*Not Available: for UPS S3 the target therapy IC75 was not found in the
therapeutic dose range considerated (pazopanib: from 30 to 5 µM).
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tumorigenic potential in vivo, are indeed resistant to conven-
tional treatments making them a clinically relevant target.
With the experimental use of doxorubicin, sorafenib (for
OS) and pazopanib (for UPS) we tried to represent realistic
chemotherapy and target drugs of well known clinical activity
in advanced STS and OS. Despite these treatments showed
responses and prolonged progression-free survival of sarcoma
patients, invariably relapses/progressions and chemo-resis-
tance/refractoriness appeared after a relatively short interval.
Our data support the notion that even when more than 50%
of the tumor mass is debulked, sCSC may escape this “first
line therapy” with relevant implications in clinical perspective.
Even if a statistical significant enrichment of sCSC (1.3
fold) was observed with targeted drugs, in our models, the
effect of CSC-sparing is much more evident with doxorubicin
compared to sorafenib or pazopanib. Indeed, the mechanisms
of resistance are likely different. In the case of doxorubicin
ATP-binding cassette membrane proteins that are more
represented in CSC are certainly involved in the so-called
multidrug resistance phenotype. TKIs are not known to be
susceptible to the same superfamily of transporters. An alter-
native hypothesis is that sCSC are commonly in more quies-
cent state and therefore less dependent on activated molecular
pathways targeted by sorafenib or pazopanib. This difference
is consistent with the absence of a direct dose-effect correla-
tion with molecular targeted drugs that is instead present with
doxorubicin in all the sarcomas explored. Even if the under-
lying mechanism may remain at a speculative level, from a
Figure 4. Phenotype of mature CIK. Representative cytofluorimetric dot plots show the typical phenotype of mature CIK. At the end of the 3–4 weeks of culture,
within mature CIK it is possible to distinguish two main T-cell subsets positive (CD3+CD56+) and negative (CD3+CD56–) for the co-expression of the CD56 molecule
(A), respectively. A high percentage of expanded CD3+ CIK expresses membrane NKG2D receptor (B) responsible of tumor target recognition. Moreover, the majority
of CIK are CD8+ (C).
Table 3. Characteristics of patients and CIK.
Pts. Age
Treaments
(n) Tumor site Basal CD3+CD56+ (%)
CD3+CD56+
(%)
CD3+CD8+
(%)
CD3+NKG2D+
(%)
Expansion
(fold)
S1 (UPS) 67 2 Local Relapse 3 51 58 80 35
S3 (UPS) 86 0 Metastasis 1 30 60 91 96
S5 (UPS) 72 0 Primitive 3 28 95 89 41
S16 (OS) 58 4 Metastasis 15 35 85 90 38
S22 (OS) 18 4 Metastasis 4 60 87 88 575
Figure 5. CIK activity against sCSC recovered after chemo and molecular targeted therapy. Patient-derived CIK efficiently killed eGFP+sCSC surviving to chemotherapy
(doxorubicin) (5A, n = 7) or target therapy (pazopanib and sorafenib) (5B, n = 8). The ratio between viable sCSC post and pre CIK-immunotherapy are reported for
each point of the killing curves. Means of tumor specific killing ± SEM are reported.
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pragmatic point of view this observation is in favor of a more
relevant anti-CSC activity of molecular targeted therapies
compared to conventional chemotherapy.
Recently published findings from other groups reported
similar results in Ewing sarcoma, liposarcoma and synovial
sarcoma cell lines treated with sorafenib, while contrasting
results were reported for pazopanib.47
We confirmed that stress-inducible ligands (MIC A/B and
ULBPs) are expressed by sCSC, at comparable levels with
those found on the rest of tumor cells, supporting the
observed susceptibility to immunotherapy with CIK.
Furthermore, we demonstrated that sCSC retain membrane
expression of HLA molecules. This observation may suggest
the conclusion that also adaptive immunotherapy approaches
may be effective. It is however important to note that we
detected only extracellular HLA chains. Tumor-associated
defects in the HLA-antigen presentation may occur at various
levels of the intracellular HLA machinery affecting antigen
processing/loading molecules, HLA-heavy chains or
beta2microglobulin.41-45,48,49
Our data, regarding chemosensitivity and immunotherapy,
are obtained without physical separation of putative sCSC that
are visualized within the bulk sarcoma cell cultures. This may
be a relevant aspect of our model as the biologic behavior and
differentiation status of putative CSC may potentially change
when extracted and separated from the surrounding tumor
progeny.
Thinking to the hypothesis of clinical translation, the best
setting for an experimental trial with CIK adoptive immu-
notherapy is likely that one of minimal residual disease fol-
lowing conventional chemo or target therapies. Based on our
preclinical findings, we could imagine that CIK may
contribute to the elimination of residual sCSC spared by
other therapies, contributing to reduce the risk of later
relapse. Our in vivo data support the chemoresistance of
sCSC and their potential susceptibility to CIK immunother-
apy. Even if CSC are considered to sustain disease relapse,
from our experimental design we can only speculate, without
drawing conclusions, about the potential “clinical” relevance
of such activity. For this purpose dedicated investigations,
with appropriate endopoints are required. For istance, at this
point a contribution of CIK-mediated inflammation to tumor
volume cannot be excluded, as we noted that at the end of the
experiment the tumor volume of mice treated with che-
motherapy-immunotherapy sequence was slightly higher
than mice treated with chemotherapy only.
CIK cells immunotherapy may be somehow easier to
explore in the field of sarcomas, where immune-checkpoint
inhibitor antibodies have not been able to replicate so far
the clinical successes obtained against melanoma and other
solid tumors. The adoptive infusion of CIK does not have
to be considered necessarily as alternative to other immu-
notherapies. Their favorable safety profile allows envision-
ing a possible integration with other approaches including
checkpoint inhibitors themselves. In fact, initial preclinical
data suggest a potential synergism as CIK express PD1 on
their membrane at variable rates. Preclinical data in this
direction were recently reported in the setting of hemato-
logic malignancies and are likely to be confirmed also in
the field of solid tumors.15,16,50-52 The cytotoxic effect of
CIK may promote a “positive” inflammation at tumor sites,
with release of tumor antigenic fragments and Th1 cyto-
kines that might in turn promote an adaptive immune
response favored by checkpoint inhibitors.
Overall our findings support the existence of a clinical
relevant subset of UPS and OS cells with stemness features
that are relatively resistant to chemotherapy, less sensitive
to molecular targeted approaches and susceptible to MHC-
independent immunotherapy with CIK. Clinical studies
are warranted to explore the activity of CIK within the
multistep and composite therapeutic strategy of advanced
sarcomas relapsing following conventional treatments.
Materials and Methods
Generation of primary sarcoma cell cultures
We successfully generated 5 primary sarcoma cell cultures, 2
OS and 3 UPS, starting from biopsies or thoracentesis of
metastatic (n = 4) or primitive (n = 1) tumor sites. All
individuals provided informed consent according to a proto-
col approved by the Internal Review Board and Ethic
Committee.
Four sarcoma cultures (S1, S3, S5 and S16) were previously
obtained from surgical biopsy and characterized by our
group.30 S22 osteosarcoma culture was generated starting
from freshly isolated thoracentesis, obtained in a sterile
vacuum bottle. Tumoral cells were isolated from fluid by
centrifugation and resuspended in KnockOut Dulbecco’s
Modified Eagle’s: Nutrient Mixture F-12 Medium (KO
DMEM:F12 medium, Gibco BRL, Life Technologies Italia)
Figure 6. Autologous CIK are active against chemo-surviving eGFP+sCSC in vivo.
Chemotherapy treatment with doxorubicin (5 mg/Kg, day 1) determined a
relative enhancement of residual sCSC (62 ± 6.8%, n = 5) while the rate of
sCSC after CIK immunotherapy (30 ± 1.7%, n = 4) remained comparable with
untreated controls (29 ± 0.3%, n = 3). The sequential chemo-immunotherapy
treatment (doxorubicin 5mg/Kg, day 1 and CIK 1 × 107 at day 5) resulted in a
relative decrease of residual viable eGFP+sCSC (37 ± 4.7%, n = 6), confirming in
vivo that CIK are equally effective against sarcomas that survived chemotherapy
treatment.
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with the addition of penicillin (50 U/ml), streptomycin (50
μg/ml), Glutamax 100X (all from Gibco BRL, Life
Technologies Italia). Cells were seeded in 10% heat-inacti-
vated Fetal Bovine Serum (FBS, Euroclone Spa), in multi-
well plates treated for anchorage-dependent cultures
(Corning/Costar, VWR International PBI S.r.l.) at clonal den-
sity (104-105 cells per cm2).
Characterization of sarcoma cell cultures
Cell aliquots were stained with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), PE–Cyanin 7 (PC7), or allophyco-
cyanin (APC)-conjugated mouse mAbs against anti-HLA-ABC-
FITC (BD Biosciences Pharmingen), anti-Sox-2-APC (Becton
Dickinson BD Biosciences Italy, Pharmingen) and CIK-target
antigens [anti-MIC A/B (BD Biosciences Pharmingen), anti-
ULBPs, anti CD112 and anti CD155 (R&D System, Space
Import Export)]. Intracellular expression of Oct4 was detected
after fixation/permeabilization by the Cytoperm/Cytofix Kit
according to the manufacturer’s instructions (BD Biosciences
Pharmingen). ALDH activity was evaluated by ALDEFLUOR
assay kit (Aldagen, Stemcell Technologies), according to man-
ufacturer’s instructions. Stro-1 expression was detected by flow
cytometric staining tumor cells with APC-conjugated anti-Stro-
1 monoclonal antibody (Biolegend). Labeled cells were read on
a FACS Cyan (Cyan ADP, Beckman Coulter s.r.l.) and analyzed
using Summit Software.
Generation of hOct4.eGFP lentiviral vector
VSV-G pseudotyped third-generation lentiviral vectors were
produced by transient 4-plasmid co-transfection into 293T
cells as described by Follenzi et al.53-55 The transfer vector
pRRL.sin.PPT.hPGK.EGFP.Wpre (LV-PGK.EGFP) was kindly
provided by Dr. Elisa Vigna and described elsewhere.
The phOct4.EGFP vector56 was kindly provided by Wei
Cui (IRDB, Imperial College London). The pRRL.sin.PPT.
hOct4. eGFP.Wpre (LV-Oct4.eGFP) was obtained by repla-
cing the expression cassette hPGK.eGFP into LV-PGK.eGFP
with the hOct4-eGFP, cleaved from phOct4-eGFP vector, by
insertion into SalI and XhoI restriction enzyme sites.30,31
Physical titers for lentiviral vector stocks were determined
on the basis of p24 antigen content (HIV-1 p24 ELISA kit;
PerkinElmer).
Sarcoma cell cultures transduction
For each lentiviral vector transduction, OS and UPS primary
cells were resuspended in fresh medium with 10% heat-inac-
tivated Fetal Bovine Serum (FBS, Euroclone Spa). Virus-con-
ditioned medium was added at dose of 400 ng P24/100,000
cells. After 16 hours, cells were washed twice and grown for at
least 10 days before flow cytometric analysis to reach steady-
state eGFP expression and to rule out pseudo transduction.
Tumorigenicity of putative sCSC
Fractions of eGFP+ and eGFP– sarcoma cells were obtained by
Flow Activated Cell Sorting (MoFlow, Beckman Coulter s.r.l.)
starting from 2 LV-Oct4.eGFP transduced UPS primary culture
(S1 and S3). To assess the tumorigenic potential of putative
eGFP+sCSC, we subcutaneously transplanted six-week-old Non-
Obese Diabetic/LtSz-scid/scid (NOD/SCID) (Charles River)
female mice with eGFP+ or eGFP– sorted UPS primary cultures
(from 2.5 × 105 to 5 × 105 cells, 2 mice for each fraction),
resuspended in sterile PBS 1X and BD Matrigel™ Basement
Membrane Matrix (Becton Dickinson BD Biosciences,
Pharmingen) 1:1.
Limiting dilution assay was performed with fractions of eGFP+
(90%) and eGFP– (96%) sarcoma cells obtained by FlowActivated
Cell Sorting (MoFlow, Beckman Coulter s.r.l.) starting from S3
LV-Oct4.eGFP transduced UPS primary cells. Six-week-old
NOD/LtSz-scid/scid (NOD/SCID; Charles River Laboratories)
female mice were subcutaneously implanted with progressively
scalar doses (7 × 104 n = 6, 7 × 103 n = 6; 7 × 102 n = 6; 7 × 101 n =
6; 7 n = 6; 0.7 n = 6) of both eGFP+ (right flank) and eGFP– (left
flank) tumor cells resuspended in equal volume of sterile PBS 1X
and BD Matrigel™ Basement Membrane Matrix (Becton
Dickinson BD Biosciences, Pharmingen). Tumor growth was
monitored weekly with calipers; volume was calculated using
formula, V = 4/3 × π × (l/2)2 × (L/2), where L is the length and l
the width diameter of the tumor. Mice were sacrificed when
tumor volume reaches a maximum of 2 cm (main diameter)
and tumors were cut into 3-mm3 pieces and processed for cell
isolation. Tumor tissue was processed by mechanical and enzy-
matic dissociation (Collagenase Type I, Invitrogen, Life
Technologies Italia) for 3 hours. Cells were then resuspended in
KnockOut Dulbecco’s Modified Eagle’s: Nutrient Mixture F-12
Medium (KO DMEM:F12 medium, Gibco BRL, Life
Technologies Italia) with the addition of penicillin (50 U/ml),
streptomycin (50 μg/ml), Glutamax 100X (all from Gibco BRL,
Life Technologies Italia); cells were seeded in 10% heat-inactivated
Fetal Bovine Serum (FBS, Euroclone Spa) and plated at clonal
density (104 – 105 cells per cm2) in multi-well plates treated for
anchorage-dependent cultures (Corning/Costar, VWR
International PBI S.r.l.). Cell aliquots were analysed by flow-
cytometry to evaluate the eGFP expression either after sorting
and explantation.
In vitro assessment of sCSC sensitivity to chemotherapy
or molecular targeted therapy
LV-Oct4.eGFP transduced sarcoma cells were treated with stan-
dardCHTandmolecular targeted therapies.We used doxorubicin
(frompharmacy leftover) asCHT for all 5 sarcomas, whilewe used
pazopanib (Selleckchem Research Product) and sorafenib
(Sequoia Research Product) as targeted therapy for UPS and OS,
respectively. Each sarcoma culture was treated with scalar doses of
drugs (doxorubicin: from 1 to 0.05 µM, pazopanib: from 30 to
5 µM, sorafenib: from 10 to 5 µM) and percentages of tumor lysis
and the rate of residual sCSCwere evaluated after 72 hours of each
treatment. LV-Oct4.eGFP transduced sarcoma cells treated with
equal volume of drug diluent have been utilized as control. At the
end of each treatment, cells were harvested and counted. The cell
viability was determined using Trypan Blue 0.1% exclusion dye
(Sigma Aldrich). The IC50 dose corresponds to IC values ranging
between 40% and 60%. While the IC75 dose corresponds to IC
values ranging between 60% and 80%. Concentrations of drugs
ONCOIMMUNOLOGY e1465161-7
that determined IC values ranging between 40% and 80% (IC50
and IC75 doses) are considered as therapeutic doses. Viable
eGFP+sCSC were determined by flow cytometry (Cyan ADP,
Beckman Coulter s.r.l.). The eGFP positivity was calculated on
viable cell fraction, detected by DAPI permeability exclusion assay
(Thermo Fisher Scientific). The eGFP enrichment, expressed as
fold increase (% of eGFP+ cells post-drug exposure/% of eGFP+
cells in untreated sample), was calculated for each experiment
separately, comparing treated samples with their internal
untreated control. After drugs treatment cell aliquots were stained
with fluorescein isothiocyanate (FITC) or allophycocyanin (APC)-
conjugated mouse mAbs against anti-HLA-ABC-PE (BD
Biosciences Pharmingen) and CIK-target antigens [anti-MIC A/
B (BD Biosciences Pharmingen), anti-ULBP3 and anti-ULBP2-5-
6 and anti-CD112 (R&D System, Space Import Export)]. Labeled
cells were read on FACSCyan (CyanADP, BeckmanCoulter s.r.l.)
and analyzed using Summit Software.
CIK culture and ex vivo expansion
CIK were expanded from peripheral blood collected from 5
patients with histologic confirmed OS and UPS at the Candiolo
Cancer Institute, Fondazione del Piemonte per l’Oncologia (FPO)
– IRCCS. All individuals provided informed consent for blood
donation according to a protocol approved by the Internal Review
Board and Ethic Committee.
PBMC were separated by density gradient centrifugation
(Lymphoprep, Aurogene s.r.l.) and seeded in cell culture
flasks at a concentration of 2 × 106 cells/mL in RPMI-1640
medium (Gibco BRL Life Technologies Italia) supplemented
with 10% fetal bovine serum (Sigma Aldrich) 100 U/mL
penicillin, and 100 U/mL streptomycin (Gibco BRL Life
Technologies Italia) at 37°C and 5% CO2. IFN-γ (Miltenyi
Biotec S.r.l.; 1000 U/mL) was added on day 0; after 24
hours the recombinant human interleukin IL-2 (Miltenyi
Biotec S.r.l.) and anti-CD3 antibody (Miltenyi Biotec S.r.l.)
were added at a concentration of 300 U/mL and 50 ng/mL,
respectively. Cells were expanded over 3 weeks of time
period. Fresh medium and IL-2 (300 U/mL) were added
weekly (every 3 days) during culture, and the cell concen-
tration was maintained at 2 – 1.5 × 106 cells/mL.
Phenotypic analyses of CIK were performed weekly, and
cytotoxic activity was assessed at the end of 3–4 weeks of
culture.
Immunophenotype
Phenotype of CIK was weekly analyzed by standard flow cyto-
metric assays. The following monoclonal antibodies (mAb) were
used: fluorescein isothiocyanate (FITC), phycoerythrin (PE), or
allophycocyanin (APC)-conjugated mouse monoclonal antibo-
dies (mAbs): CD3–FITC, CD8–PE, CD56–APC/PE and
CD314–APC (aka anti-NKG2D) (mAbs) (CD3, CD8 and
CD56 from BD Biosciences Italy, Pharmingen; anti-NKG2D
from Miltenyi Biotec S.r.l.). Labeled cells were read on FACS
Cyan (Cyan ADP, Beckman Coulter s.r.l.) and analyzed using
Summit Software.
In vitro assessment of CIK cells activity against sCSC that
survive chemotherapy or molecular targeted therapy.
CIK tumor-killing ability was assessed against 5 LV-Oct4.
eGFP transduced sarcoma cultures previously treated for 72
hours with IC50 dose of doxorubicin (0.1 µM), or pazopanib
(30 µM), or sorafenib (5 µM) and or with equal volume of
diluent as control. The effector cells were assayed where
possible against autologous tumor targets (4/5). In absence
of autologous PBMC (S22) we utilized as allogeneic effectors,
CIK generated from a third party metastatic OS patient. The
CIK immune-mediated killing was analyzed by flow cytome-
try (Cyan ADP, Beckman Coulter s.r.l.) by DAPI permeability
assay (Thermo Fisher Scientific) of target cells. CIK were co-
cultured with either autologous or allogeneic sarcoma cells
with a 40:1, 20:1, 10:1, 5:1, 2,5:1, 1:1, 1:2 and 1:4 effector/target
ratio for 72 hours in 200 µL of medium with IL-2 at a
concentration of 300 U/mL at 37°C 5% CO2. Target cells
were stained with PKH26 Red Fluorescent Cell Linker kit
(Sigma Aldrich) or with the vital dye CFSE (5, 6-carboxy-
fluorescein diacetate succinimidyl ester; Molecular Probes) in
accordance with the manufacturer’s protocol. As confirmation
test, a method of determining the number of viable cells in
culture based on quantitation of the ATP present, an indicator
of metabolically active cells (CellTiter-Glo® Luminescent Cell
Viability Assay, Promega Italia s.r.l) has been utilized (data
not shown). Tumor cells plated in the absence of CIK were
used as a control to assess spontaneous mortality. The per-
centage of tumor-specific lysis for each effector/target ratio
was calculated according to the following formula: (experi-
mental-spontaneous mortality/100 – spontaneous mortality) x
100. To evaluate the percentage of the residual eGFP+ cells
viable at each effector/target ratio of the killing curve, a
duplicate of the cytotoxicity test was plated using tumor target
not previously stained with PKH26 Red Fluorescent Cell
Linker kit or with the vital dye CFSE. The percentage of viable
eGFP+ cells was determined by flow cytometry (Cyan ADP,
Beckman Coulter s.r.l.) in any point of the immunotherapy
CIK killing curve. The eGFP positivity was calculated on
viable cell fraction, detected by DAPI permeability exclusion
assay (Thermo Fisher Scientific). The enrichment (fold) of
viable sCSC was calculated as the ratio between residual
percentage of sCSC post and pre CIK immunotherapy for
each point of the immunotherapy killing curve.
In vivo activity of chemotherapy and CIK-immunotherapy
against sCSC
Six-week-old NOD/LtSz-scid/scid (NOD/SCID; Charles River
Laboratories) female mice were subcutaneously injected with 3 ×
106 LV. Oct4.eGFP–transduced patient-derived sarcoma cells (S1,
n = 18) resuspended in sterile PBS 1X and BDMatrigel™Basement
Membrane Matrix (Becton Dickinson BD Biosciences,
Pharmingen) 1:1. Treatments started when tumors became palp-
able.Mice from chemotherapy group (n = 11) received a single tail
vein injection of doxorubicin (5 mg/kg, day 1). Mice from CIK
immunotherapy group (n = 4) received 3 intravenous infusions (1
× 107/injection, days 1, 3, 5) of autologous mature CIK cells
(resuspended in 200 mL of PBS 1X) while mice injected with
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PBS 1X alone (n = 3) represented untreated controls. To explore
the sequential treatment with chemotherapy and CIK immu-
notherapy, 6mice from theCHT cohort (treatedwith doxorubicin
on day 1) received an intravenous infusionwith CIK cells (1 × 107/
mouse, day 5). Tumor growth was monitored every 2 days with
calipers and volume calculated according to the formula: V = 4/3 ×
π × (l/2)2 × (L/2), where L is the length and l the width diameter of
the tumor. 72 hours from the last treatment (day 8), animals were
euthanized and the recovered tumors were processed by mechan-
ical and enzymatic dissociation using the Tumor Dissociation kit,
human and the gentleMACS dissociator, according to the manu-
facturer’s instructions (Miltenyi Biotec S.r.l.). Single cell suspen-
sions thus obtained were enriched of human tumor cells with the
mouse cell depletion kit (Macs Miltenyi Biotec.) and the percen-
tage of eGFP+ cells was determined by flow cytometry (CyAn
ADP, Beckman Coulter s.r.l.) and analyzed using Summit
Software.
The volume fold increase was calculated according to the
formula:
Tumor volume at day of sacrifice/Tumor volume 72 hours
before treatment started.
Statistical analysis
Descriptive analyses of CIK and sarcoma features were reported as
median values and ranges, or mean ± SEM, as appropriate. The
relative increase of eGFP+ sCSC after treatments in vitro was
reported as fold change compared to untreated controls. The
statistical significance was calculated by one sample t-test, trans-
forming each fold change into the corresponding log2 value. The
mixed model analysis of variance (ANOVA) was employed to
assess CIK cytotoxic activity curves in vitro. P value concerning
the tumor onset frequency in limiting dilution assaywas calculated
with Fisher’s exact test.
Results with p value < 0.05 were considered as statistically
significant.
Data were analyzed by software GraphPad Prism 6.
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